Related Experiment Video
Updated: May 13, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal sympathetic denervation for treating resistant hypertension
Alberto Polimeni1, Antonio Curcio, Ciro Indolfi
1Division of Cardiology, Laboratory of Molecular and Cellular Cardiology, Department of Medical and Surgical Sciences, Catanzaro, Italy.
Summary
Resistant hypertension, often unresponsive to medication, can be treated by reducing kidney nerve activity. Renal sympathetic denervation using catheter ablation offers a new therapeutic option for managing high blood pressure.
Area of Science:
- Cardiology
- Nephrology
- Vascular Biology
Background:
- Systemic hypertension is a major global health concern, leading to significant morbidity and mortality.
- Resistant hypertension, characterized by persistent high blood pressure despite medication, affects a substantial patient population.
- Renal sympathetic overactivity plays a key role in the pathophysiology of hypertension.
Purpose of the Study:
- To review the role of sympathetic activation in hypertension.
- To discuss transcatheter renal sympathetic denervation as a treatment for resistant hypertension.
- To explore future directions in hypertension management.
Main Methods:
- Review of existing literature on sympathetic nervous system and hypertension.
- Analysis of data on catheter-based renal sympathetic denervation procedures.
- Evaluation of clinical outcomes, including blood pressure reduction and biochemical markers.
Main Results:
- Renal sympathetic denervation effectively reduces renal norepinephrine spillover and renin activity.
- The procedure leads to increased renal plasma flow.
- Clinically significant and sustained blood pressure reductions were observed in patients with resistant hypertension.
Conclusions:
- Renal sympathetic denervation is a promising therapeutic strategy for resistant hypertension.
- Targeting renal sympathetic nerves offers a novel approach to managing systemic hypertension.
- Further research is needed to optimize targets for future hypertension management.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...